《礼来-JPM-20240109.pdf》由会员分享,可在线阅读,更多相关《礼来-JPM-20240109.pdf(12页珍藏版)》请在三个皮匠报告上搜索。
1、1 2024 Eli Lilly and Company DAVE RICKSChair and CEO,Eli Lilly and CompanyJ.P.Morgan Healthcare ConferenceJanuary 9,20242 2024 Eli Lilly and Company Safe Harbor ProvisionThis presentation contains forward-looking statements that are based on managements current expectations,but actual results may di
2、ffer materially due to various factors.The companys results may be affected by factors including,but not limited to,the risks and uncertainties in pharmaceutical research and development;competitive developments;regulatory actions;litigation and investigations;business development transactions;econo
3、mic conditions;and changes in laws and regulations,including health care reform.For additional information about the factors that affect the companys business,please see the companys latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission.Certain financia
4、l information in this presentation is presented on a non-GAAP basis.Investors should refer to the reconciliations included in this presentation and should consider the companys non-GAAP measures in addition to,not as a substitute for or superior to,measures prepared in accordance with GAAP.The compa
5、ny undertakes no duty to update forward-looking statements except as required by applicable law3 2024 Eli Lilly and Company NOT FOR PROMOTIONAL USELong-term performance underpinned by innovation focus,while obesity TAM*was the dominant narrative in 2023An eventful and productive 6 yearsLLY+653%DRG+6
6、3%DRG(ex-LLY&NVO)+21%1/9/201812/29/2023*TAM=Total Addressable Market4 2024 Eli Lilly and Company NOT FOR PROMOTIONAL USEAccelerating R&D timelinesSubstantial investment in each therapeutic area and in genetic medicines,with accelerated R&D timelinesFocus and speed have helped drive R&D productivityC
7、oncentrated bets in areas of high unmet needFOCUSConcentrated bets in areas of high unmet needSPEEDAccelerated R&D timelinesDiabetes,Obesity&CardiometabolicPortfolio Entry to First Human Dose(Years)First Human Dose to First Launch(Years)3.62015-2017OncologyNeuroscienceImmunology2.42021-20239.92011-2
8、0156.22019-20231.Through Q3 2023.(1)(1)5 2024 Eli Lilly and Company NOT FOR PROMOTIONAL USE$0$2$4$6$8$10$12$020202120222023R&DAcquired In-Process R&DR&D spend has nearly doubled since 2018,while Acquired IPR&D has increased with business development activityConsistent and growing R&D inve
9、stment1.Excludes animal health R&D before completion of Elanco spin-off in September 2018.2.2023 R&D figure based on midpoint of financial guidance;2023 IPR&D through Q3.(2)USD billions(1)6 2024 Eli Lilly and Company NOT FOR PROMOTIONAL USE6Discovering and delivering breakthrough medicines requires
10、persistence of R&D effortsThe long road to“overnight”success in incretins2002Lilly-Amylin alliance for exenatide signed2010Proof of concept in mice of weight loss from GIP+GLP-12014FDA approval for Trulicity(dulaglutide once weekly injection)2017Tirzepatide Phase 2 trial in T2D begins2023Zepbound ap
11、proved by FDA for chronic weight management2005Approval of Byetta2010AWARD-1 Phase 3 study of dulaglutide in T2D begins2022Mounjaro(tirzepatide)launches for T2D;SURMOUNT-MMO tirzepatide outcomes study in obesity begins2019Trulicity REWIND CV outcomes study positive readout1996Dr.John Eng licenses ex
12、endin-4 to AmylinFirst in human data of tirzepatide showing weight lossBody Weight Change(kg)Days20177 2024 Eli Lilly and Company NOT FOR PROMOTIONAL USE$0$50$100$150$200$250$0$10$20$30$40$50$60$70$80$90$100NPV of NME Portfolio+Recent Launches($B)Total R&D Pipeline Investment($B)Lilly productivity b
13、oosted by tirzepatide,but remains above industry line ex-tirzepatideHow does R&D productivity scale?excl.tirzepatideData Sources:y-axis:EvaluatePharma Consensus Estimates for current NME pipelines and NME launches since 2014,as of 12/7/2023x-axis:Company reported R&D OPEX+estimated one-time M&A expe
14、nditures for pipeline assets,2017-2022NOT FOR PROMOTIONAL USE8 2024 Eli Lilly and Company NOT FOR PROMOTIONAL USE50%of our NME pipeline is from acquisition,licensing,or partnershipExternal innovation in Lillys pipelineSelect NMEs shared from Q3 2023 earnings materialsPHASE 2PHASE 1REG REVIEWPHASE 3L
15、EGENDAT2R ANTAGONIST PainCD19 ANTIBODY ImmunologyDACRA QW IIObesityDC-853ImmunologyNOT DISCLOSED PainFGFR3 SELECTIVECancerGIPR AGONIST LA DiabetesGIPR AGONIST LA II DiabetesGITR ANTAGONISTImmunologyNOT DISCLOSEDDiabetesNOT DISCLOSED NeurodegenerationKRAS G12C IICancerKV1.3 ANTAGONIST ImmunologyAMYLI
16、N AGONIST LAObesityMAZDUTIDE ObesityNRG4 AGONISTHeart FailureNISOTIROSTIDEDiabetesPI3K SELECTIVE CancerPNPLA3 siRNANASHSARM1 INHIBITORNeurodegenerationAPOC3 siRNACVDRET INHIBITOR IICancerRIPK1 INHIBITORRheumatoid ArthritisUCENPRUBARTAtopic DermatitisBimagrumab ObesityDC-806PsoriasisELTREKIBARTHidrad
17、enitis Suppurativa LEPODISIRANCVDMUVALAPLINCVDO-GLCNACASE INHAlzheimers DiseaseP2X7 INHIBITORPainPERESOLIMABRheumatoid ArthritisGBA1 GENE THERAPYParkinsons DiseaseGRN GENE THERAPYFrontotemporal Dementia VOLENRELAXIN Heart FailureSOLBINSIRAN CVDSSTR4 AGONISTPainMEVIDALENSymptomatic LBDIMLUNESTRANTER+
18、HER2-mBCINSULIN EFSITORA ALFADiabetesORFORGLIPRONObesityREMTERNETUG Alzheimers DiseaseRETATRUTIDEObesity,OA,OSAOTOF GENE THERAPYHearing LossDONANEMABAlzheimers DiseaseLEBRIKIZUMABAtopic DermatitisSCAP siRNANASHACQUISITIONLICENSING/PARTNERSHIPINTERNALLY DISCOVERED&DEVELOPEDPhase 3 in China with Innov
19、ent for T2DM and Obesity9 2024 Eli Lilly and Company NOT FOR PROMOTIONAL USE9 2024 Eli Lilly and Company We aim to maximize value of acquisitions post-transaction with employee retention and a flexible approach to integrationM&A is only one approach to external innovation 200222023NOT FOR
20、 PROMOTIONAL USE10 2024 Eli Lilly and Company NOT FOR PROMOTIONAL USEServing as an investor and strategic partner to the global ecosystemBringing an exceptional site experience to biotechSharing decades of enterprise learning,from scientific to technical know-how LILLY GATEWAY LABSSPACELILLY VENTURE
21、SVENTURE CAPITALLillys catalyze360 is a broader approach to external innovation focused on meeting a variety of partner needsWe are engaging the biotech ecosystem in multiple waysLILLY ExploR&DRESEARCH&DEVELOPMENT11 2024 Eli Lilly and Company NOT FOR PROMOTIONAL USEMaintain focus on the convergence of unmet medical need and large patient populationsSustain discipline on threshold for molecule developmentIncrease breadth of partnerships for early innovationBe early on new modalities and technologiesDriving excellence at scale for patients 2024 Eli Lilly and Company